Epilepsy drug study for kids halted early: what we know

NCT ID NCT05301894

Terminated Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at the long-term safety of a drug called NBI-827104 in children with a rare epilepsy that causes seizures during sleep. The trial was stopped early and only enrolled 19 children, so the results are limited. The main goal was to see how many children had serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NBI-827104 (a drug that blocks T-type calcium channels in the brain)
What this could lead to: If successful, this could point toward a treatment option for children with this rare form of epilepsy.
What could go wrong: The study was terminated early with only 19 participants, so we have very limited data on safety or effectiveness. It is still in early testing (Phase 2).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTINUOUS SPIKE AND WAVE DURING SLEEP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

developmental and epileptic encephalopathy developmental and/or epileptic encephalopathy with spike-wave activation in sleep epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTINUOUS SPIKE AND WAVE DURING SLEEP EPILEPTIC ENCEPHALOPATHY

Contacts and locations

Locations

Neurocrine Clinical Site

Orange, California, 92868, United States
Neurocrine Clinical Site

Aurora, Colorado, 80045, United States
Neurocrine Clinical Site

Washington D.C., District of Columbia, 20010, United States
Neurocrine Clinical Site

Miami, Florida, 33155, United States
Neurocrine Clinical Site

Rochester, Minnesota, 55905, United States
Neurocrine Clinical Site

Durham, North Carolina, 27705, United States
Neurocrine Clinical Site

Cleveland, Ohio, 44195, United States
Neurocrine Clinical Site

Dianalund, 4293, Denmark
Neurocrine Clinical Site

Barcelona, 08950, Spain
Neurocrine Clinical Site

Madrid, 28034, Spain
Neurocrine Clinical Site

Zurich, 8032, Switzerland
Neurocrine Clinical Site

London, WC1N 3JH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.